Tom Brady's Cloned Dog Sparks Biotech Ethics Debate
Former NFL star Tom Brady's revelation of cloning his late dog, Lua, has brought pet cloning into the spotlight, reigniting ethical discussions around genetic engineering. Brady is an investor in Colossal Biosciences, a company that facilitated the cloning.
The company also acquired Viagen Pets, known for cloning pets for celebrities. This move bolsters Colossal's capabilities for its ambitious de-extinction projects, including reviving species like the woolly mammoth.
However, animal welfare organizations like PETA and the ASPCA have voiced strong opposition due to low success rates, potential health issues in cloned animals, and the existence of millions of adoptable pets in shelters. They call for a moratorium on pet cloning.
Colossal Biosciences maintains its commitment to animal welfare, citing Viagen's extensive experience and asserting that cloned animals live comparable lives to their counterparts. The company argues its work is crucial for conservation efforts and addressing environmental crises.


Cryptovka
Genetic Frontier: Tom Brady
The world of biotechnology is increasingly blurring the lines between science fiction and reality, with implications that resonate across various s...








